NCT02223286

Brief Summary

The purpose of this study is to understand the use of Corus CAD also known as Age/Sex/Gene Expression score (ASGES) in the clinical decision making process of patients who underwent the evaluation of chest pain or anginal equivalent symptoms. Specifically, to better understand whether the use of the assay in clinical decision making resulted in changes in noninvasive diagnostic test ordering or diagnostic yield of additional tests ordered and/or invasive angiography.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
552

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2013

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

August 19, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 22, 2014

Completed
Last Updated

February 22, 2018

Status Verified

February 1, 2018

Enrollment Period

1.3 years

First QC Date

August 19, 2014

Last Update Submit

February 21, 2018

Conditions

Keywords

Corus CADASGESAge/Sex/Gene Expression ScoreGene ExpressionGESCADCVDCHDPrecision MedicineClinical UtilityCoronary Artery DiseaseAngina PectorisChest PainCardiovascular DiseaseCoronary Heart DiseaseUCU-CARD

Outcome Measures

Primary Outcomes (1)

  • The primary measure of this study is the number of advanced diagnostic tests in ASGES (treatment group) patients compared to the number of advanced diagnostic tests in non-ASGES (control group) patients.

    The primary study endpoint was the percentage of patients for whom advanced diagnostic testing was ordered-stress testing with imaging, computed tomography angiography, or invasive coronary angiography.

    up to 24 months

Study Arms (2)

ASGES (Treatment Group)

Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD

Diagnostic Test: Corus CAD

Non-ASGES (Control Group)

Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD

Interventions

Corus CADDIAGNOSTIC_TEST

Age/Sex/Gene Expression Score

ASGES (Treatment Group)

Eligibility Criteria

Age21 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patient population of interest and the main inclusion criterion for inclusion is the occurrence of chest pain (or anginal equivalent) in a patient without known significant CAD or a history of prior myocardial infarction, and the utilization of Corus CAD (Age/Sex/Gene Expression score - ASGES). Additionally, subjects with similar chest pain (or angina equivalent) whom did not undergo Corus CAD (ASGES) will be included as a control group, to understand the diagnostic evaluation and management of patients prior to Corus CAD (ASGES) use.

You may qualify if:

  • Symptoms suggestive of CAD, according to the opinion of the site clinician
  • Age \>= 21 years

You may not qualify if:

  • History of myocardial infarction (MI)
  • History of high risk unstable angina, systemic infections or systemic inflammatory conditions
  • Current MI or acute coronary syndrome
  • Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms
  • Known/documented CAD
  • History/current Diabetes Mellitus
  • Taking steroids, immunosuppressive agents, or chemotherapeutic agents, at time of chest pain presentation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

John C. Lincoln Heart Institute

Phoenix, Arizona, 85037, United States

Location

Piedmont Heart Institute

Blue Ridge, Georgia, 30513, United States

Location

Heart Associates

Youngstown, Ohio, 44504, United States

Location

MeSH Terms

Conditions

Coronary Artery DiseaseAngina PectorisChest PainCardiovascular DiseasesCoronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • David Hoffman, DO

    Northeast Ohio Medical University

    PRINCIPAL INVESTIGATOR
  • Lawrence Kline, DP

    John C. Lincoln Heart Institute

    PRINCIPAL INVESTIGATOR
  • Jaime Burkle, MD

    Piedmont Heart Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2014

First Posted

August 22, 2014

Study Start

March 1, 2013

Primary Completion

June 1, 2014

Study Completion

August 1, 2014

Last Updated

February 22, 2018

Record last verified: 2018-02

Locations